Literature DB >> 9794111

Long-term treatment in vivo with NOX-101, a scavenger of nitric oxide, prevents diabetes-induced endothelial dysfunction.

G M Pieper1, K Dembny, W Siebeneich.   

Abstract

Substantial evidence exists that diabetes results in impaired endothelial dysfunction suggesting diminished nitric oxide production from diabetic endothelium. It is not known what factors contribute to the development of this defect. In this study, we tested whether chronic treatment in vivo with NOX-101, a water-soluble nitric oxide scavenger, prevents endothelial dysfunction in diabetes. Sprague-Dawley rats were made diabetic by an intravenous injection of streptozotocin. A subgroup of control or diabetic animals received twice daily subcutaneous injections of 80 mg/kg NOX-101 beginning at 48 h after streptozotocin was injected and throughout 8 weeks of diabetes. Body weights and glucose concentrations were monitored weekly. At the end of 8 weeks, blood glucose and glycosylated haemoglobin was raised in diabetic rats but serum insulin concentrations were reduced. Treatment with NOX-101 did not alter glucose or insulin concentrations in control or diabetic rats; however, total glycosylated haemoglobin was partially reduced compared with untreated rats. In a subgroup of 2-week diabetic and age-matched rats fasted for 24 h, NOX-101 abolished total urinary nitrate plus nitrite (an index of nitric oxide production in vivo). In isolated tissue baths, relaxation to the endothelium-dependent vasodilator, acetylcholine, was impaired in diabetic aortic rings and relaxation to nitroglycerin was unaltered. Treatment of control rats with NOX-101 did not alter maximum relaxation to acetylcholine but shifted the response curve slightly to the right. In contrast in diabetic rats, NOX-101 prevented the impairment in endothelium-dependent relaxation but had no effect on relaxation induced by nitroglycerin. These data suggest the possibility that diabetes-induced endothelial dysfunction in diabetes results, in part, from a paradoxical increase in nitric oxide production during the course of the disease. This suggests a novel pathway of vascular complications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794111     DOI: 10.1007/s001250051055

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  4 in total

Review 1.  Obstructive sleep apnea: the new cardiovascular disease. Part I: Obstructive sleep apnea and the pathogenesis of vascular disease.

Authors:  Rami Khayat; Brian Patt; Don Hayes
Journal:  Heart Fail Rev       Date:  2008-09-20       Impact factor: 4.214

2.  Endothelial dysfunction in the microcirculation of patients with obstructive sleep apnea.

Authors:  Brian T Patt; David Jarjoura; Diane N Haddad; Chandan K Sen; Sashwati Roy; Nicholas A Flavahan; Rami N Khayat
Journal:  Am J Respir Crit Care Med       Date:  2010-07-23       Impact factor: 21.405

3.  Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications.

Authors:  Assunta Pandolfi; Elena Anna De Filippis
Journal:  Genes Nutr       Date:  2007-10-17       Impact factor: 5.523

4.  Increased nitric oxide activity compensates for increased oxidative stress to maintain endothelial function in rat aorta in early type 1 diabetes.

Authors:  A Joshi; O L Woodman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-11       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.